Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

0
17
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has accepted for Priority Review the supplemental Biologics License Application for Dupixent® as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
[Regeneron Pharmaceuticals, Inc.]
Press Release